Objectives Despite the publication of hundreds of trials on gout and hyperuricemia,
management of these conditions remains suboptimal. We aimed to assess the quality and …

Background and aims Chloroquine (CQ) and hydroxychloroquine (HCQ) are widely used in
patients with rheumatic diseases, but their effects on the cardiovascular system remain …

Background To evaluate the effects of proprotein convertase subtilisin/kexin 9 (PCSK9)
inhibitors on major adverse cardiovascular events (MACE). Methods Our systematic review …

Introduction Gout and hyperuricaemia are major health issues and relevant guidance
documents have been released by a variety of national and international organisations …

Present evidence suggests that the administration of antibiotics, particularly
aminopenicillins, may increase the risk of rash in children with infectious mononucleosis …

Background/objectives Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is
increasingly used in obese or overweight patients with diabetes. However, its safety profile …

Abstract Background The Core Outcome Measures in Effectiveness Trials (COMET) working
group proposed core outcome sets (COS) to address the heterogeneity in outcome …

Background An increasing number of systematic reviews (SRs) have evaluated the
diagnostic values of next-generation sequencing (NGS) in infectious diseases (IDs). Aim …

Background Antimicrobial resistance (AMR) is a serious global health threat and leads to a
huge challenge to infectious diseases (ID) treatment. To tackle AMR, regional 'Antimicrobial …

Background Revefenacin (REV) is a novel once-daily long-acting muscarinic antagonist
(LAMA) in the treatment of moderate to very severe chronic obstructive pulmonary disease …